In colorectal cancer, it appears that loss of ARID1A in wild-type backgrounds may promote early tumorigenesis while loss of ARID1A in the background of mutations in APC or KRAS may inhibit tumor progression (Fig. 6d). This evidence concerns the gene ARID1A and colorectal cancer.